

1601
N. Tucson Blvd. Suite 9
Tucson, AZ 85716-3450
Phone: (800) 635-1196
Hotline: (800) 419-4777
|
Association
of American Physicians and Surgeons, Inc.
A Voice for Private Physicians Since 1943
Omnia pro aegroto |
ASSOCIATION OF AMERICAN PHYSICIANS AND SURGEONS
POSITION PAPER ON GENETIC TESTING
Introduction and Executive Summary
Medical tests can now identify genetic traits in people not
showing symptoms or external signs. Some of these conditions
can produce disease later in life, or in some offspring. In
the context of risk assignment for health insurance, these
genetic tests have recently become controversial.
AAPS finds that genetic testing is not fundamentally
different from other tests or examinations used to assign
people to insurance risk categories. Such information is
currently confidential and restricted to legally and morally
appropriate usage and disclosure, regardless of the origin
of the data. In private insurance markets, genetic testing
poses no inherently unique or new problem requiring
additional government legislation or regulation. However,
the use of such tests by government for social engineering
is fraught with dangers.
To help preclude dangerous use of such testing and to allow
Americans more complete exercise of their inalienable
rights, AAPS recommends
1) requiring any person to be individually liable in the
event of unlawful disclosure of genetic testing information
(as well as in other civil matters) by repealing sovereign
immunity protection of government employees, and
2) allowing Americans greater freedom of choice in health
insurance, such as the freedom to choose insurance either
with or without genetic testing.
The Concept of Insurance
Historically, "natural" insurance was created to protect
assets against unlikely but statistically predictable
accidents. (1,2,3) For example, centuries ago, ship owners
risked loss of ships and cargo due to unpredictable storms,
uncharted reefs and human error. Nevertheless, they knew
that only a small number of ships would be lost in any one
year and that these losses tended to average out over a
number of years. Several owners voluntarily agreed among
themselves to mutually protect each other against such
losses; they pooled funds to pay a ship owner who lost a
ship in an accident. This was essentially a form of
"indemnity" insurance; the pooled funds were essentially
premiums paid in exchange for mutual protection. Ship owners
facing lesser risk of loss, such as those sailing only in
more protected waters, could insure themselves by
contributing smaller amounts to their own pools.
Natural insurance thus groups or pools people with similar
risks together by charging similar premiums. Risk against
unlikely and expensive events is divided among the insured
people. Later, separate companies were formed to mutually
manage the risk assessment, premiums and administration on
behalf of the insured people, and were called "mutual"
companies, essentially a partnership of the insured people.
Later, "stock" companies took on themselves the risk for
losses rather than the pool of insured people and sold
insurance, in exchange for the hope of profit. The insured
people had the benefit of a contractual relationship with an
independent party and were protected from losses inherent in
a mutual company arrangement; the stock insurance company
had the chance to make a profit in exchange for assuming the
risk. But the basic function - dividing the risk of unlikely
expenses among people facing similar risks - remained the
same. Insurance provided a mechanism for people to
voluntarily share and divide risk, enhancing human freedom.
Health Insurance
A century ago, available forms of health insurance were
largely variations of natural insurance, providing a set
amount of money in the event of death or accidental injury.
In the 1930s, early Blue Cross and Blue Shield plans started
offering medical service benefits rather than paying a set
amount if specified injuries or death occurred.
In the 1940s employee health insurance and medical expenses
were made an income-tax-deductible business expense.
Employees and employers found it mutually advantageous to
buy health insurance through the employer. Because of the
tax advantage, this health coverage was extended to cover
routine expenses in addition to unlikely and unpredictable
expenses. Thus, by the 1970s "health coverage" no longer
acted as natural insurance but sometimes paid for nearly all
small, expected, or discretionary medical care. Though
unlikely and unpredictable events were still covered in
employer-provided health coverage, much of the coverage
amounted to pre-payment for the consumption of health care
services, rather than natural insurance.
More recently, several states have required insurance
companies to "guarantee" issue of health insurance,
regardless of any condition or disease the person might
have. This are often called a "guaranteed issue"
requirements; we call this a form of "social insurance." (In
this context, we use "social insurance" to mean providing
benefits sought by politicians to fulfill political goals,
whether through direct government action or through
regulations and mandates placed on others, in this case,
insurance companies.) As was expected by some, these
requirements make this insurance more expensive. For many
individuals and families, health insurance is no longer
worth the expense and has become "unaffordable."
Politicians rarely admit that legislation is the primary
cause of the problem. As some studies predicted, fewer
people now have health insurance in these states. (4)
Essentially, these states force consumers to pay for "social
insurance" under penalty of law and essentially outlaw
"natural" health insurance. In other words, insurance
companies are forced to do unnatural things to meet
political agendas, and are not allowed to offer insurance at
realistic, actuarial rates reflecting risk. Likewise, these
bureaucratic requirements demean responsible individuals and
families, and constrict human choice and freedom.
Genetic Testing
In the context of this statement, "genetic testing" is
similar to other examinations for the purpose of assigning a
person to an insurance risk class. For example, these
examinations include medical history, physical examination,
family history, blood tests, electrocardiogram and other
physiological examinations. Assessing risk is a natural
insurance function as it allows insurance companies to
assess the individual's risk and assign the person to the
appropriate risk pool and corresponding premium. Thus, those
at lower risk for an expensive event are charged less, while
those at higher risk are charged more. For instance, mature
adults in their 40s and 50s have a lower than average
automobile accident rate and pay lower premiums. Young males
have a much higher accident rate than average and cause
disproportionately higher payouts by insurance companies;
insurance companies charge these young men higher premiums
reflecting the higher risk. Thus, the higher rates for young
males allows people in other groups to purchase
reasonably-priced insurance. The variation in rates also
lets young men know that driving is more expensive for them;
this probably reduces accidents, as some young men decide
that insurance is not worth the cost and do not drive.
In addition to its potential value in assessing insurable
risks, genetic testing has likely medical and individual
benefits. For instance, such testing is now available for
Huntington's Disease, an autosomal dominant genetic
disorder; affected individuals suffer early dementia,
psychosis, movement disorder, and death. Symptoms do not
start until about age 30. Unlike most genetic traits and
conditions, only a single gene transmits the condition to
children. [Sidebar or footnote? Genes are carried on the
chromosomes in the nucleus of human germ cells. Germ cells
are the cells that transmit genetic information to children.
Each parent provides one of a pair of chromosomes to each
child. Therefore, each child has a 50% chance of inheriting
the condition if one of the parents carries the Huntington's
Disease gene.]
Testing for Huntington's Disease can be helpful to people
with a family history of the condition. Knowing whether or
not they have the gene producing the condition can allow
these people to better plan and organize their life. Because
those carrying the gene for the disorder can pass on that
gene before they show any symptoms, knowledge about having
or not having the disorder can have very significant effects
on others, such as a possible spouse or possible children.
Likewise, genetic testing for colon cancer traits could be
valuable to individuals who could then modify their diet and
exercise habits to reduce the likelihood of developing the
cancer.
As with all medical evaluations, varying degrees of accuracy
are associated with genetic testing, which limits the
predictive or prognostic value of many tests. These accuracy
variations are due to many factors, such as the complexity
of the human genome, the interaction of many genes,
variations in technique, and variations in interpretation.
Also, interactions between genetic traits and the
environment are not we;; understood; incorrect
interpretation of findings could incorrectly associate
genetic findings with physical or other traits. For example,
in the now discredited field of phrenology, the shape of the
head was related to intelligence and other traits. Publicity
about phrenology in France caused a fad of head binding to
change the shape of the skull, in an attempt to cause the
child to grow up with the positive traits associated with
the desired head shape.
Thus, people with a family history of genetic disorders but
who are found to not carry the disordered gene on testing
could purchase health and life insurance at standard rates.
Without such testing, insurance companies would be justified
in charging more to all individuals who could possibly be at
risk. Thus many people might pay lower rates than they would
have without genetic testing. If a person did have the gene
for a genetic disorder, natural insurance could still be
available in many cases but would be more expensive. In
addition, modified standard insurance could be available,
which cover other unpredictable medical problems, but not
cover the genetic condition. In any event, it is likely that
insurance would be more available and/or affordable for a
larger number of people.
It is unfortunate that some people carry genetic disorders.
It is unfortunate that such disorders may entail large
medical expenses and disability. However, it is a fact of
life that diverse individuals have diverse intelligence,
looks, and upbringing, all of which affect their lives to
various degrees. People with knowledge of their own genetic
disorders have more opportunity to manage their own future
and fate. Families and friends are in a better position to
help. Others can also help these individuals, such as
through charitable organizations. Private organizations and
insurance companies can help set up high risk pools to help
these individuals purchase insurance. If government
involvement is required to help meet the needs of otherwise
uninsurable people, high risk pools have been much more
effective and efficient than guaranteed issue and similar
regulatory efforts.
[Irrelevant side thought: In addition, advances in
biochemistry and pharmacology are likely to allow treatment
for many genetic conditions. Thus, the demand for genetic
testing for therapeutic reasons will likely expand further
in the future. It is likely that such therapy will be much
more expensive. (David Ranney MD, personal communication)
Insuring against such conditions would be correspondingly
expensive. Thus, allowing freedom of choice in insurance
will likely be a practical as well as financial necessity.
Those willing to insure could do so. Those willing to
purchase therapy directly could also do so.]
In a natural insurance market, genetic testing could provide
further information allowing more accurate risk assessment
and insurance policy pricing. This could permit more
individuals to afford reasonably-priced policies. Thus, if
reducing the number of uninsured people is an important
policy consideration, competitive pricing of insurance
products should be a priority.
Further, part of the cost of insurance compensates for the
variability of risk between individuals; it is therefore
quite possible that the cost of insurance might decrease, if
the testing results in significantly more accurate risk
assessment.
With "one size fits all" legislative mandates, all insurance
companies might be required to test or not to test for
certain medical condition. But some insurance companies
might well find that they do not want to try to "fine tune"
their risk pools by requiring extensive testing, or they
might find a market among those who don't want to undergo a
lot of painful or time-consuming medical tests. Thus,
freedom from mandates provides wider consumer choice among
insurance products.
In addition, with social insurance or with government
controlling or regulating most of the medical market and the
practice of medicine, certain tests might be mandated by
government, despite subsequent evidence of ineffectiveness
or even counter-effectiveness. Indeed, government policy
makers in many agencies have suppressed scientific evidence
or terminated innovative scientific studies because the
discovered scientific facts would require change in
established government policy, to the disadvantage of the
bureaucrats' jobs or power. A similar process of
bureaucratic sclerosis and self-serving would likely affect
genetic testing if government becomes further involved in
health care financing and decision making.
Judging from historical experience, only government power
brokers and their favored agents ultimately benefit when
legislation and regulation distort the workings of natural
markets, including the natural insurance market. The vast
majority of citizens find themselves paying more for less
effective insurance and more bureaucratic interference in
their lives.
Concerns Over Genetic Testing
As with other tests, some people are reluctant to learn
something inherent and permanent about their biological
condition. Many people are concerned about possible loss of
their privacy. In a natural insurance market, the potential
loss of privacy in undergoing genetic testing involves the
same trade-offs as providing other confidential information,
such as your medical history; it is information voluntarily
traded for the opportunity to enter the insurance risk pool.
A normally functioning natural insurance market tends to
preserve the confidentiality of the medical information.
Currently, health insurance companies share such information
in private arrangements with other companies; this saves the
expense of repeating tests and helps augment the
individual's medical history, which results in more
efficient and cost-effective risk assignment. Government
health agencies maintain similar information on government
patients. History shows that this information will sometimes
be leaked or misused, regardless of who controls it. When
private companies leak information and break people's
confidence, they have often been exposed and punished, as
people no longer buy their services or sue. In contrast,
when government agencies do the same, the guilty bureaucrats
have often been protected and rewarded instead of suffering
meaningful consequences.
Genetic testing could be used for purposes found immoral in
the Hippocratic medical tradition. For example, a
utilitarian use of testing, in this example also immoral,
would be to test for conditions which would make an
individual less useful to society for the purpose of killing
that person, as has been done in some totalitarian systems,
such as Nazi Germany. Likewise, the use of genetic testing
in attempts to breed a super race would be immoral and
unethical. In these examples, the utility of the person to
the society is the deciding factor, a position antithetical
to the Hippocratic tradition of primary responsibility to
the individual patient rather than to an amorphous society
or relativistic social policies.
Because of these dangers, we find that all individuals in
America, should be held to the same standard of behavior
before the law. We find that "sovereign immunity" for
government employees and agencies for actions which would be
illegal for private citizens is neither pertinent nor
appropriate for Americans. We believe that government
officials would be much more responsible and responsive if
they were held to the same legal and moral standards as
other Americans.
Summary
It is the position of the Association of American Physicians
and Surgeons that genetic testing for insurance purposes,
like other innovations, has potentially advantageous as well
as potentially harmful effects. If used to provide
information to more accurately evaluate risk, such testing
could beneficially increase the effectiveness and efficiency
of a natural health insurance market and could allow more
fair pricing of insurance services. This would likely
increase the ability of more individuals to purchase
reasonably priced or affordable insurance.
Similarly, other measures, such as providing equal
protection and responsibility for all citizens before the
law, eliminating guaranteed issue requirements, abolishing
mandated benefits, and establishing tax equity in the
purchase of health insurance would also advance the options
and freedoms of Americans.
The Association of American Physicians and Surgeons calls
for stringent confidentiality of medical information
maintained by all insuring agencies, whether private
insurance carriers or government enterprises. Currently
provided confidentiality should be enhanced with equal
protection of individuals regardless of whether the insuring
agency is private or governmental. Significant incentives to
maintain confidentiality and penalties for violations of
confidentiality should be required of all insuring
enterprises.
Endnotes
1 E F Haislmaier, "A Policy Maker's Guide to the Health Care
Crisis," Part III, August 14, 1992 and Part IV, November 5,
1992, Heritage Foundation Washington D.C.
2 Michael Tanner, "Health Care Reform: the Good, the Bad and
the Ugly," Policy Analysis No. 184, November 24, 1992, Cato
Institute, Washington D.C.
3 Catherine England, The Business and Regulation of
Insurance: A Primer, March 1996, Competitive Enterprise
Institute, Washington D.C..
4 Melinda Schriver and Grace-Marie Arnett, "Uninsured Rates
Rise Dramatically in States with Strictest Health Insurance
Regulations", Backgrounder No. 1211, August 14, 1998, The
Heritage Foundation, Washington, D.C.
|